CIK: 0001388325
Total reported value
$1.2B
Reporting period: 2026-03-31 · Number of holdings: 22
NOVO HOLDINGS A/S disclosed 22 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.2B and a quarterly turnover rate of 28.7%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "N"
Novo Holdings A/s's disclosed holdings carry a Herfindahl concentration index of 0.074 — mathematically equivalent to about 14 equally-sized positions, close to its 22 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.80), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 3.2 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 33% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add EWTX
0.0% $35.8M
Trim VRDN
-16.0% -$34.9M
Add ELVN
-13.5% $27.4M
Add MIRM
+4.8% $22.6M
Trim CRNX
-4.6% -$19.3M
Trim VALN
-54.1% -$13.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics INC | Stock-Other | 13.65% | +3.34% | — | |
| 2 | BN | Brookfield CORP | Stock-Financials | 11.46% | -1.00% | — | |
| 3 | ASML | ASML Holding N.V. | Stock-Tech | 10.16% | +0.69% | -16.67% | |
| 4 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 9.92% | +2.17% | +4.82% | |
| 5 | MPLT | Maplight Therapeutics INC | Stock-Other | 6.07% | +1.04% | — | |
| 6 | CRM | Salesforce INC | Stock-Tech | 5.95% | -0.84% | +19.08% | |
| 7 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 4.56% | -1.31% | -4.62% | |
| 8 | ELVN | Enliven Therapeutics INC | Stock-Other | 4.07% | +2.30% | -13.51% | |
| 9 | PCVX | Vaxcyte INC | Stock-Other | 4.05% | +0.77% | -6.13% | |
| 10 | PHVS | Pharvaris N.V. | Stock-Other | 4.01% | +0.24% | — | |
| 11 | AVBP | Arrivent Biopharma INC | Stock-Other | 3.63% | +0.60% | — | |
| 12 | VRDN | Viridian Therapeutics INC | Stock-Other | 3.17% | -2.58% | -15.97% | |
| 13 | CLDX | Celldex Therapeutics INC | Stock-Other | 3.08% | +0.55% | — | |
| 14 | APGE | Apogee Therapeutics INC | Stock-Other | 3.07% | -0.27% | -21.05% | |
| 15 | BMRN | Biomarin Pharmaceutical INC | Stock-Healthcare | 3.02% | -0.03% | — | |
| 16 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.75% | +0.62% | — | |
| 17 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 2.62% | -0.31% | — | |
| 18 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 2.29% | +2.29% | NEW | |
| 19 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.59% | -0.32% | +11.45% | |
| 20 | VALN | Valneva Se - Adr | Stock-Other | 0.54% | -1.04% | -54.12% | |
| 21 | LNZA | Lanzatech Global INC | Stock-Other | 0.21% | +0.04% | — | |
| 22 | MQ | Marqeta Inc-a | Stock-Other | 0.15% | -0.01% | — |
Performance for Q3 2026
+19.5%
Performance Last 4 Quarters
+81%
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 22 | $1.2B | 29 | |
| 2025-12-31 | 24 | $1.3B | 51 | |
| 2025-09-30 | 27 | $1.6B | 39 | |
| 2025-06-30 | 29 | $1.4B | 0 | |
| 2025-03-31 | 31 | $1.3B | 100 | |
| 2024-12-31 | 34 | $1.7B | 0 | |
| 2024-09-30 | 37 | $2.0B | 0 | |
| 2024-06-30 | 38 | $1.9B | 0 | |
| 2024-03-31 | 35 | $1.4B | 0 | |
| 2023-12-31 | 36 | $1.6B | 0 | |
| 2023-09-30 | 40 | $1.4B | 0 | |
| 2023-06-30 | 41 | $1.3B | 0 | |
| 2023-03-31 | 47 | $1.5B | 0 | |
| 2022-12-31 | 48 | $1.6B | 0 | |
| 2022-09-30 | 52 | $2.1B | 0 | |
| 2022-06-30 | 54 | $2.0B | 0 | |
| 2022-03-31 | 51 | $1.9B | 0 | |
| 2021-12-31 | 48 | $2.1B | 0 | |
| 2021-09-30 | 49 | $1.9B | 0 | |
| 2021-06-30 | 54 | $2.3B | 100 | |
| 2021-03-31 | 51 | $2.4B | 45 | |
| 2020-12-31 | 45 | $2.3B | 49 | |
| 2020-09-30 | 42 | $2.0B | 34 | |
| 2020-06-30 | 35 | $1.5B | 52 | |
| 2020-03-31 | 30 | $1.5B | 21 | |
| 2019-12-31 | 29 | $1.6B | 97 | |
| 2019-09-30 | 29 | $583.7M | 36 | |
| 2019-06-30 | 29 | $713.8M | 58 | |
| 2019-03-31 | 22 | $676.0M | 36 | |
| 2018-12-31 | 23 | $710.3M | 100 | |
| 2018-09-30 | 22 | $1.3B | 0 | |
| 2018-06-30 | 18 | $991.1M | 0 | |
| 2018-03-31 | 17 | $797.4M | 28 | |
| 2017-12-31 | 14 | $713.4M | 37 | |
| 2017-09-30 | 17 | $768.3M | 23 | |
| 2017-06-30 | 21 | $835.8M | 45 | |
| 2017-03-31 | 22 | $939.1M | 70 | |
| 2016-12-31 | 22 | $1.1B | 41 | |
| 2016-09-30 | 17 | $1.1B | 25 | |
| 2016-06-30 | 18 | $952.6M | 28 | |
| 2016-03-31 | 17 | $912.5M | 32 | |
| 2015-12-31 | 14 | $1.0B | 40 | |
| 2015-09-30 | 19 | $967.9M | 40 | |
| 2015-06-30 | 19 | $1.4B | 34 | |
| 2015-03-31 | 15 | $1.2B | 12 | |
| 2014-12-31 | 15 | $1.2B | 27 | |
| 2014-09-30 | 13 | $1.0B | 20 | |
| 2014-06-30 | 10 | $1.0B | 23 | |
| 2014-03-31 | 8 | $811.0M | 23 | |
| 2013-12-31 | 7 | $681.0M | 51 | |
| 2013-09-30 | 5 | $403.8M | 43 | |
| 2013-06-30 | 4 | $597.0M | 3 |
Novo Holdings A/s's most significant position changes for 2026-03-31: Sold out: Zenas Biopharma INC (ZBIO); Sold out: Insmed INC (INSM); New buy: Xenon Pharmaceuticals INC (XENE); Sold out: Io Biotech INC (IOBTQ); Trim: Viridian Therapeutics INC (VRDN) — shares -15.97%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics INC | +3.3% | — | Unchanged |
| 2 | ELVN | Enliven Therapeutics INC | +2.3% | -13.51% | Trim |
| 3 | MIRM | Mirum Pharmaceuticals INC | +2.2% | +4.82% | Add |
| 4 | MPLT | Maplight Therapeutics INC | +1% | — | Unchanged |
| 5 | PCVX | Vaxcyte INC | +0.8% | -6.13% | Trim |
| 6 | ASML | ASML Holding N.V. | +0.7% | -16.67% | Trim |
| 7 | FDMT | 4d Molecular Therapeutics In | +0.6% | — | Unchanged |
| 8 | AVBP | Arrivent Biopharma INC | +0.6% | — | Unchanged |
| 9 | CLDX | Celldex Therapeutics INC | +0.6% | — | Unchanged |
| 10 | PHVS | Pharvaris N.V. | +0.2% | — | Unchanged |
| 11 | LNZA | Lanzatech Global INC | 0% | — | Unchanged |
| 12 | MQ | Marqeta Inc-a | 0% | — | Unchanged |
| 13 | BMRN | Biomarin Pharmaceutical INC | 0% | — | Unchanged |
| 14 | APGE | Apogee Therapeutics INC | -0.3% | -21.05% | Trim |
| 15 | BABA | Alibaba Group Holding-sp Adr | -0.3% | — | Unchanged |
| 16 | BBOT | Bridgebio Oncology Therapeut | -0.3% | +11.45% | Add |
| 17 | CRM | Salesforce INC | -0.8% | +19.08% | Add |
| 18 | BN | Brookfield CORP | -1% | — | Unchanged |
| 19 | VALN | Valneva Se - Adr | -1% | -54.12% | Trim |
| 20 | CRNX | Crinetics Pharmaceuticals In | -1.3% | -4.62% | Trim |
| 21 | VRDN | Viridian Therapeutics INC | -2.6% | -15.97% | Trim |
| 22 | ZBIO | Zenas Biopharma INC | — | EXIT | Sold out |
| 23 | INSM | Insmed INC | — | EXIT | Sold out |
| 24 | XENE | Xenon Pharmaceuticals INC | — | NEW | New buy |
| 25 | IOBTQ | Io Biotech INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-10-24 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-20 | Amendment | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-27 | Amendment | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2019-02-06 | Amendment | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2019-02-06 | Amendment | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-16 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-11-14 | Amendment | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-11-14 | Amendment | View on EDGAR |
| 2014-03-31 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-11-14 | Amendment | View on EDGAR |
| 2013-12-31 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2013-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2013-06-30 | 2014-11-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001805114
Total reported value
$1.2B
298 stks
2025-12-31
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001039128
Total reported value
$1.2B
1,211 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001660424
Total reported value
$1.2B
1 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000315054
Total reported value
$3.0B
12 stks
2026-03-31
2 of the top 5 holdings overlap, including ASML Holding N.V.
CIK 0000040417
Total reported value
$1.5B
69 stks
2026-03-31
1 of the top 5 holdings overlap, including ASML Holding N.V.
CIK 0000314965
Total reported value
$7.4B
228 stks
2019-06-30
Stale — no recent filing
1 of the top 5 holdings overlap, including ASML Holding N.V.